NAVROGEN Fc-Engineered Monoclonal Antibodies Targeting ICAM-1/CD54 for Cancer Treatment
Summary
USPTO published patent application US20260098858A1 for NAVROGEN, INC. covering Fc-engineered monoclonal antibodies with CH3 region modifications designed to reduce ICAM-1/CD54 binding, improving immune-effector activity and antibody drug conjugate killing for cancer and inflammatory disease treatment.
What changed
USPTO published patent application US20260098858A1 disclosing Fc-engineered monoclonal antibodies with CH3 region modifications that reduce ICAM-1/CD54 binding, thereby enhancing antibody immune-effector activity and antibody drug conjugate efficacy. The invention covers compositions and methods for treating patients with cancer and inflammatory and infectious diseases exhibiting elevated ICAM-1/CD54 levels.
Pharmaceutical companies and biotechnology firms developing monoclonal antibody therapeutics should monitor this filing as it represents NAVROGEN's potential competitive position in the ICAM-1/CD54 targeting space. If granted, the patent could restrict competitor development of similar Fc-engineered antibodies for the specified therapeutic applications.
What to do next
- Monitor for updates on patent prosecution status
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Fc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD54
Application US20260098858A1 Kind: A1 Apr 09, 2026
Assignee
NAVROGEN, INC.
Inventors
James Bradford Kline, Nicholas C. Nicolaides, Luigi Grasso
Abstract
The ICAM-1/CD54 protein has been found to be a suppressor of antibody-mediated humoral immunity facilitated through its direct binding to the CH3 domain within IgG1 heavy chains. Its binding suppresses antibody immune-effector activity by reducing IgG1 engagement with Fc receptors on effector cells and C1q complement initiating protein. In addition, its binding has the potential to reduce antibody drug conjugate activity by slowing target cell internalization. Engineered antibodies with CH3 region modifications can be generated that reduce or eliminate ICAM-1/CD54 binding leading to antibodies with improved immune-effector activity and antibody drug conjugate killing in the presence ICAM-1/CD54. These antibodies can be useful to treat patients with cancer and inflammatory and infectious diseases exhibiting elevated ICAM-1/CD54 levels.
CPC Classifications
G01N 33/5011 C07K 16/2821 C40B 30/06 G01N 33/6845 C07K 2317/732
Filing Date
2023-08-14
Application No.
19104036
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.